Datopotamab Deruxtecan vs MT-302

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline

Datopotamab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in Non-Small Cell Lung Cancerantibody-drug conjugate
Partial signal

NCT04656652 · Phase 3 · active, not recruiting

This open-label, randomized Phase III trial (TROPION-Lung01) assigned 604 patients with previously treated advanced or metastatic non-small cell lung cancer to datopotamab deruxtecan or docetaxel. It had two primary endpoints, progression-free survival and overall survival. Progression-free survival improved significantly (hazard ratio 0.75, P=.004), but overall survival showed only a numerical benefit that did not reach statistical significance (hazard ratio 0.94, P=.530). One primary was met and one was missed, so the result is mixed. Source: the peer-reviewed paper (Ahn et al., J Clin Oncol 2025).

Next expected readout: January 2027 · NCT06417814 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel (From randomization until disease progression or death (whichever occurs first), up to approximately 27 months); Overall Survival (OS) Following DS-1062a Versus Docetaxel (From randomization until date of death due to any cause, up to to approximately 38 months): Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025). (mixed)

Result source: NCT04656652

MT-302

Developed by CREATE Medicines

gene therapy
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDatopotamab DeruxtecanMT-302
PFS, median4.4 vs 3.7vs Docetaxel6.0 mg/kg · n 299NCT04656652
1 other result
  • 4.4 vs 3 6.0 mg/kg · n 299 · Phase 3 · secondary NCT04656652
—Not reported
OS, median12.9 vs 11.8vs Docetaxel6.0 mg/kg · n 299NCT04656652—Not reported
ORR35.8%b6.0 mg/kg Q3W · n 137NCT04484142—Not reported
Duration of response, median—Trial running · NCT04656652—Not reported

PFS, median

Datopotamab Deruxtecan
4.4 vs 3.7vs Docetaxel6.0 mg/kg · n 299NCT04656652
1 other result
  • 4.4 vs 3 6.0 mg/kg · n 299 · Phase 3 · secondary NCT04656652
MT-302
—Not reported

OS, median

Datopotamab Deruxtecan
12.9 vs 11.8vs Docetaxel6.0 mg/kg · n 299NCT04656652
MT-302
—Not reported

ORR

Datopotamab Deruxtecan
35.8%b6.0 mg/kg Q3W · n 137NCT04484142
MT-302
—Not reported

Duration of response, median

Datopotamab Deruxtecan
—Trial running · NCT04656652
MT-302
—Not reported
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

MT-302: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Datopotamab Deruxtecan: 4 of 4 rows · MT-302: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDatopotamab Deruxtecan
Dropout rate
77.3%6.0 mg/kga
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
85.4%6.0 mg/kg Q3W
NCT04484142 · Phase 2
Discontinued due to AEs
—6.0 mg/kga
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
9.5%6.0 mg/kg Q3W
NCT04484142 · Phase 2
Serious AEs
31%6.0 mg/kga
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
24.8%6.0 mg/kg Q3W
NCT04484142 · Phase 2
Most frequent reported AEs
6.0 mg/kga
stomatitis 49.8%
nausea 37.7%
alopecia 32%
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
6.0 mg/kg Q3W
nausea 59.9%
stomatitis 57.7%
alopecia 51.1%
NCT04484142 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Datopotamab Deruxtecan

PFS 4.4 vs 3.7 Docetaxel months6.0 mg/kg
time to event · months
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
4.4 vs 3 Docetaxel months6.0 mg/kg
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival 12.9 vs 11.8 Docetaxel months6.0 mg/kg
time to event · months
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 26.4% (n=299) vs 12.8% (n=305) Docetaxel6.0 mg/kg
event count · % of participants
Assessed by Blinded Independent Central Review
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to % from 79 Participants as posted
Duration of Response 7.1 vs 5.6 Docetaxel months6.0 mg/kg
time to event · months
Assessed by Blinded Independent Central Review
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 35.8% (n=137)6.0 mg/kg Q3W
responder rate · % of participants
No placebo or comparator arm
NCT04484142 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Datopotamab Deruxtecan's landscape · MT-302's landscape